The class-I histone deacetylases (HDACs) HDAC1 and HDAC2 belong to a family of 11 zinc-dependent human HDACs and are overexpressed in many cancers. Inhibitors of these HDACs now in clinical trials show activity against several types of cancers. This review is focused on recent advances in both clinical and preclinical efforts to understand the basis for the actions of HDACis, with emphasis on implications for rational combinations with conventional or other targeted agents. We will address new perspectives on the molecular mechanisms by which HDACs act and how these actions relate to cancer. We will also review new evidence showing that HDACs are direct intracellular targets of the potent sphingolipid mediator S1P, the first identified endogenous nuclear regulator of these enzymes, linking sphingolipid metabolism in the nucleus to remodeling of chromatin and epigenetic regulation of gene expression. Understanding how endogenous molecules regulate HDAC activity in vivo may facilitate the search for safer and more effective anticancer drugs capable of interfering with HDAC functions in a highly specific manner.
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Background on HDACs
Acetylations and deacetylations of histones have emerged as a critical component of an epigenetic indexing system demarcating transcriptionally active chromatin domains. This dynamic balance is regulated by two important families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs) (Clayton et al., 2006) . HATs catalyze the acetylation of lysine residues, neutralizing positive charges, relaxing chromatin structure and increasing the accessibility of the transcription machinery. HDACs remove acetyl groups from histones (and other nuclear proteins), thereby inducing chromatin condensation and transcriptional repression (Yang and Seto, 2008; Haberland et al., 2009) , and have emerged as key targets to reverse aberrant epigenetic changes associated with cancer (Minucci and Pelicci, 2006; Glozak and Seto, 2007; Marks, 2010) .
Recent data provide evidence that both HATs and HDACs are targeted to transcribed regions of active genes and that the majority of HDACs in the human genome function to reset chromatin by removing the acetylation of histones at active genes (Wang et al., 2009) . Moreover, inhibition of HDACs showed that they have two major roles: First, to remove acetyl groups at active genes added by HATs during transcriptional initiation and elongation in order to maintain a sufficient level of acetylation to enable specific transcriptional elongation and prevent promiscuous initiation, and second, to remove acetyl groups added by transient binding of HATs at inactive gene promoters to maintain a reduced level of acetylation and to prevent Pol-II from binding. This work also provided an example of how the order of implementation of histone modifications can affect transcription (Wang et al., 2009) . They showed that treatment of cells with HDAC inhibitors (HDACis) does not lead to productive transcription, despite the presence of H3K4 methylation and Pol-II recruitment (Wang et al., 2009) . This, together with other data, led to the suggestion that patterns of histone modifications cannot simply be 'read' but instead have distinct effects depending on the cellular context and upstream signaling events (Lee et al., 2010b) .
HDACs are expressed in all eukaryotic cells and HDAC activity is essential for cell proliferation, differentiation and homeostasis. Eighteen HDACs have been identified in humans that are classified based on their homology to yeast HDACs (Figure 1 ). Eleven of these HDACs contain highly conserved deacetylase domains and are zinc-dependent: class-I (HDAC1, 2, 3 and 8 have homology to yeast RPD3); class-IIa (HDACs 4, 5, 7 and 9 have homology to yeast HDA1); class-IIb (HDACs 6 and 10 have two catalytic sites) and class-IV (HDAC11, has conserved residues shared with both class-I and class-II deacetylases). The different classes differ in structure, enzymatic activity, localization and expression pattern. In contrast to class-I HDACs, class-IIa have low enzymatic activity, and it has been suggested that they may have evolved to maintain low basal activities with acetyl-lysines and to efficiently process restricted sets of specific, unknown natural substrates (Lahm et al., 2007) . Class-IIb HDACs have primarily non-epigenetic functions and regulate protein folding and turnover (Boyault et al., 2007) . In addition to these classical HDACs, another group of deacetylases, known as class-III or sirtuins, has been recognized. This seven-member family requires NAD for enzymatic activity, is not homologous to the classical HDAC superfamily and will not be discussed here.
Class-I HDACs are expressed in all tissues, have significant HDAC activity and are primarily localized in the nucleus where they are present in multi-protein complexes with transcription factors and co-repressors that are targeted to specific genetic loci crucial for transcriptional repression and epigenetic landscaping. HDACs form the catalytic core of mega-dalton complexes involved in chromatin modification and gene repression. The HDAC1-HDAC2 dimer is in the CoREST, NuRD and Sin3 complexes, whereas HDAC3 has been found in the NCoR complex (Yang and Seto, 2008) . The roles of these four molecular complexes are diverse and often cell type-specific.
Overexpression of specific HDACs has been observed in many types of cancer and often correlates with poor prognosis (Figure 1 ). For example, HDAC1 is overexpressed in gastric, pancreatic, colorectal, prostate and hepatocellular cancers, and correlates with poor prognosis (Choi et al., 2001; Zhang et al., 2005; Rikimaru et al., 2007; Fritzsche et al., 2008; Miyake et al., 2008; Weichert et al., 2008) . HDAC2 is mutated in colon cancer and is overexpressed in esophageal, prostate, non-small-cell lung, gastrointestinal and oral cancers (Ropero et al., 2006; Fritzsche et al., 2008; Weichert et al., 2008; Chang et al., 2009) . Poor prognosis in gastric, prostate, colorectal cancers and chronic lymphocytic leukemia (CLL) correlates with HDAC3 expression (Krusche et al., 2005; Fritzsche et al., 2008; Weichert et al., 2008; Moreno et al., 2010) . HDAC8 is overexpressed in CLL and correlates with poor outcome in neuroblastoma (Oehme et al., 2009; Moreno et al., 2010) . Whereas low expression of HDAC5 in lung cancer is associated with poor prognosis, its expression is upregulated in colon cancer (Osada et al., 2004; Ozdag et al., 2006) . Although HDAC6 is expressed at low levels in lymphoma, there are high levels in CLL, and expression in oral squamous cell cancer correlates with stage (Sakuma et al., 2006; Gloghini et al., 2009; Moreno et al., 2010) . Much less is known of the relationship of the other HDACs with cancer. Because abundant evidence indicates that HDAC1 and HDAC2 are overexpressed in many cancers (Figure 1) , and their expression correlates with poor prognosis in many cases, our remarks will mainly be focused on these two HDACs. Studies of HDAC-knockout mice and inhibition of HDACs with class-I-selective inhibitors indicate that class-I HDACs are important for cell survival and proliferation (Marks, 2010) . Of interest, transcriptional regulation of cyclin-dependent kinase inhibitor-1 (p21) is one of the most extensively studied targets of class-I HDACs (Ocker and Schneider-Stock, 2007) . Disruption of hdac1 causes early embryonic lethality owing to decreased proliferation resulting from increased expression Figure 1 The human HDAC superfamily showing domain organization and cancer relevance. HDACs are grouped into different classes according to sequence similarity. Blue indicates the conserved catalytic domain; the asterisks indicate nuclear localization signals; ZnF, zinc finger, myocyte enhancer factor-2 (MEF2)-binding motifs are depicted as short turquoise cylinders and 14-3-3 chaperone-binding motifs are shown as short yellow cylinders labeled with 'S' (for serine phosphorylation sites).
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S Spiegel et al of p21 (Lagger et al., 2002) . Likewise, inactivation of HDAC2 increases p21 expression and HDAC2 overexpression correlates with reduced p21 expression (Huang et al., 2005) . Deletion of HDAC3 also delayed cell-cycle progression and induced DNA damage and apoptosis (Bhaskara et al., 2008) . It is well known that class-I HDACs can regulate the transcription of many other genes encoding proteins involved in the control of cell growth, apoptosis, tumorigenesis and angiogenesis. However, over the past decade, it has become apparent that in addition to histones HDACs can deacetylate numerous non-histone proteins that regulate cellular functions (Glozak and Seto, 2007) . Of this steadily growing list of non-histone targets, the most important are transcription factors, which are often considered to be 'master immune regulators;' the signal transducers and activators of transcription, Stat1 (signal transducer and activator of transcription-1) and Stat3; and nuclear factor-kB (NF-kB) subunits, whose functions are regulated by acetylation/deacetylation and are known be important in inflammation and tumorigenesis. For example, N-terminal acetylation of Stat3 has been suggested to be important for its nuclear localization, dimerization and transcriptional activity (Yuan et al., 2005; Ray et al., 2008) . By contrast, HDAC1, HDAC2 and HDAC3 are necessary for Stat1-dependent gene activation, as silencing of these HDACs or their inhibition blocks the induction of interferon-stimulated Stat1 target gene expression (Nusinzon and Horvath, 2003) . p65 acetylation/deacetylation may be functionally important as endogenous p65 is acetylated in response to several stimuli, and deacetylation of specific lysine residues on p65 by HDAC1, HDAC3 or SIRT1 has been proposed to be involved in the termination of NF-kB responses by decreased transcriptional activity and/or its nuclear export (Calao et al., 2008) . Another important example is a-tubulin, which is effectively deacetylated by class-IIb HDAC6 (Hubbert et al., 2002) . The ability of class-II HDACs to shuttle between the nucleus and the cytoplasm may be related to this important cytoplasmic function. Interestingly, many proteins post-translationally modified by acetylation that are deacetylated by HDACs have key roles in oncogenesis and tumorigenesis. As noted previously, HDACs might not be the most accurate name for all of these enzymes, and they should more appropriately be referred to as acetyl-lysine deacetylases (Walkinshaw et al., 2008) .
HDACis in cancer therapy
Because HDACs are frequently dysregulated in transformed cells (Marks, 2010) , the development of HDACis has become the subject of intense interest, and many of these agents have now entered the clinical arena. Critical questions remaining to be resolved are whether HDACi isoform specificity offers therapeutic advantages, or whether more broadly acting HDACis (that is, pan-HDACis) will prove to be superior in the clinic. The theoretical advantage of isoform-specific inhibitors is that they have the capacity to target selectively those HDACs that are dysregulated in a particular cancer type, thus avoiding possible host toxicity stemming from the inhibition of other HDACs. On the other hand, pan-HDACis, and particularly those that inhibit class-IIb HDACis (Hubbert et al., 2002; Valenzuela-Fernandez et al., 2008) , have the advantage of targeting multiple cellular processes, including those involved in protein disposition (see below). For example, the ability of class-IIb HDACis to disrupt aggresome function (Bali et al., 2005) may be particularly important in interactions between such compounds and other targeted agents, for example, tyrosine kinase inhibitors that target mutant oncoproteins (Fiskus et al., 2006) . The development of selective HDACis with anticancer activities remains challenging in part because of the difficulty of probing the interaction of small molecules with mega-dalton protein complexes. A recent study used 'chemoproteomics', a combination of affinity capture and quantitative mass spectrometry profiling, to show selective targeting of HDAC complexes by known HDACis (Bantscheff et al., 2011) . This group showed that HDACis with distinct profiles have different effects on downstream targets, suggesting that evaluation of the selectivity of HDACis in the context of HDAC complexes, and not only with purified catalytic subunits, is important for the development of new selective HDACis (Bantscheff et al., 2011) .
It is still not understood completely why HDACis are relatively more toxic to transformed cells than to normal cells. This phenomenon may reflect the genetic dysregulation characteristic of malignant cells and/or an impaired capacity of such cells to respond to noxious stimuli as compared with their normal counterparts. For example, it has long been recognized that HDACis can kill cells through oxidative injury and induction of reactive oxygen species (ROS) (Ruefli et al., 2001; Rosato et al., 2003b) . It has also been shown that upon exposure to HDACis, transformed cells show a very limited ability to induce cytoprotective antioxidant proteins, such as thioredoxin, compared with normal cells, and consequently generate significantly more ROS (Ungerstedt et al., 2005) . More recently, it has been shown that following HDACi treatment, transformed cells show reductions in DNA-repair proteins (for example, RAD50, MRE) and are selectively impaired in their ability to repair DNA damage (Lee et al., 2010a) . It is therefore possible that the selectivity HDACis exert toward transformed cells represents the combined consequences of increased ROS generation in neoplastic cells in conjunction with disruption of DNA-repair processes. Whether these events are responsible for or contribute to the therapeutic index of HDACis remains to be determined.
To date, two HDACis have been approved for the treatment of cancer, that is, the pan-HDACi vorinostat and the cyclic peptide romidepsin have been approved for the treatment of refractory cutaneous T-cell lymphoma . Clinical trials involving these and additional HDACis are underway in other lymphomas, that is, peripheral T-cell lymphoma, and initial results appear promising. The underlying basis for the unique sensitivity of these malignancies to HDACis remains to be fully elucidated, but clues bearing on this question have emerged recently. These studies suggest that expression of HR23B, a gene whose protein product has been implicated in shuttling ubiquitinated proteins to the proteasome for degradation, may represent a useful biomarker for responses to HDACis in cutaneous T-cell lymphoma (Fotheringham et al., 2009; Khan et al., 2010) . Whether HR23B in involved in regulating the responses of other tumor cell types to HDACis remains to be determined.
Because HDACis act through multiple mechanisms, they are particularly well suited to rational combination strategies involving either conventional cytotoxic agents or other targeted agents. In the case of the former, the ability of HDACis to induce chromatin relaxation has been invoked to explain synergism with certain DNAinteractive agents for example, topoisomerase-II inhibitors (Marchion et al., 2004) . In the case of the latter, attention has focused on strategies combining HDACis with proteasome inhibitors. Such interactions may involve multiple mechanisms, including interference (that is, by proteasome inhibitors) with HDACi-mediated NF-kB activation (Dai et al., , 2008b , as well as disruption of aggresome function and induction of proteotoxic stress (Hideshima et al., 2005) . Notably, early results of trials combining HDACs with proteasome inhibitors have shown promise in patients with refractory multiple myeloma (Badros et al., 2009) , and such efforts are being expanded in other malignancies. In preclinical studies, synergistic interactions between HDACis and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) have been attributed to the upregulation of death receptors (Insinga et al., 2005) and/or to the simultaneous interruption of the intrinsic and extrinsic apoptotic pathways (Rosato et al., 2003a) . In addition, pan-HDACis that prevent tubulin and Hsp90 deacetylation have been shown to interact synergistically with tyrosine kinase inhibitors targeting oncogenic proteins requiring chaperone function for their survival for example, Bcr/Abl Bali et al., 2005) . HDACis have also been reported to increase the sensitivity of lung cancer cells by upregulating E-cadherin (Witta et al., 2006; Lagger et al., 2010) , and, as a consequence of their actions as antiangiogenic agents, to potentiate the activity of angiogenesis inhibitors in prostate and breast carcinoma cells (Qian et al., 2004) . The ability of HDACis to upregulate the proapoptotic protein Bim has been invoked to account for synergism between these agents and BH3 mimetics such as ABT-737 in human leukemia cells (Chen et al., 2009) . Finally, considerable attention has focused on coordinated strategies designed to promote the re-expression of silenced tumor-suppressor genes by simultaneously increasing histone acetylation (by HDACis) and diminishing the methylation of CpG islands (that is, by DNAmethyltransferase inhibitors (DNMTIs)) (Cameron et al., 1999; Gore et al., 2006; Luszczek et al., 2010) .
A recent study by Sharma et al. (2010) on the development of tolerance to anticancer drugs by cancer cells showed that it is a transient phenotype acquired at low frequency, with hypersensitivity to HDAC inhibition, altered chromatin and an intrinsic ability to tolerate drug exposure. While the in vivo significance of the cell culture findings needs to be established, this hypersensitivity to HDACis has the potential to provide a therapeutic opportunity to prevent the development of drug resistance.
Mechanisms of action of HDACis: new perspectives
The mechanism(s) by which HDACis exert their antineoplastic effects remains the subject of considerable debate, but there is now general agreement that these agents most likely act through multiple interacting processes. In the most general sense, HDACis influence transformed cell behavior through five interrelated mechanisms. First, HDACis modify the acetylation status of gene promoters, which regulates gene expression (Bolden et al., 2006) (Figure 2) . Second, by neutralizing the acidic charges on histone tails, HDACis promote chromatin relaxation, which is generally more conducive to gene transcription (Marks, 2010) . However, it is important to recognize that the effects of HDACis do not always favor gene activation, as downregulation of certain genes may also occur in response to these agents (Mitsiades et al., 2004) . Besides their direct effects, HDACis also prevent the deacetylation of multiple transcription factors, including NF-kB, STAT3 and YY1, among numerous others, thereby controlling their activity (Chen et al., 2002) . Consequently, HDACis may regulate gene expression directly, by preventing or reversing the deacetylation of promoters, or indirectly, by altering chromatin structure and/ or by influencing transcription factor function (Figure 2 ). In addition to transcription factors, HDACis also promote the acetylation of a large number of non-histone proteins, which may influence their function. These include chaperone proteins (for example, Hsp90), DNA-repair proteins (for example, Ku70), tubulin, nuclear receptors and hypoxia-inducible factor-1a, among numerous others (Buchwald et al., 2009) (Figure 2 ). It is not hard to envision that such direct and indirect actions of HDACis might cooperate to determine cell fate. For example, HDACis induce the downregulation of DNA-repair genes and acetylation of DNA-repair proteins; induce cell-cycle arrest at the G 1 /S boundary by upregulation of p21 and/or downregulation of cyclins; and suppress angiogenesis by decreased expression of pro-angiogenic factors (vascular endothelial growth factor, hypoxia-inducible factor-1a and cytokines (tumor necrosis factor-a, interleukin-1)). Finally, HDACis may act, at least in part, by disrupting interactions between HDACs and co-repressors implicated in transformation (Cerchietti et al., 2011) .
With this background in mind, the mechanisms of HDACi lethality can be grouped into several broad categories, summarized below. Particular emphasis has been placed on emerging insights into the role of ROS generation and DNA damage as determinants of HDACi lethality.
Modulation of the expression/function of Bcl-2-family members HDACis have been reported to upregulate the expression of proapoptotic proteins, and to downregulate the expression of antiapoptotic proteins through activation of the intrinsic, mitochondrial apoptotic pathway. For example, HDACis upregulate Bim through an E2F-dependent mechanism (Zhao et al., 2005) . HDACi-mediated upregulation of Noxa and Puma has also been described (Chen et al., 2007) . Conversely, HDACis have been shown to downregulate the expression of Bcl-2, Bcl-xL, XIAP and Mcl-1 (Gillespie et al., 2006) .
As noted previously, HDACis may also activate the extrinsic, receptor-mediated apoptotic pathway by upregulating death receptor expression (DR4, DR5, Fas) (Insinga et al., 2005; Nebbioso et al., 2005) . Such a mechanism may help to explain the ability of HDACis to activate Bid (Ruefli et al., 2001) . In agreement, valproic acid synergized with TRAIL to induce the apoptosis of pancreatic cancer cells by a mechanism involving increased expression of TRAIL receptor-1 (DR5), accelerated processing of caspase-8, pronounced cleavage of the BH3-only protein Bid and increased effector caspase activation suggesting a strategy to overcome TRAIL resistance in pancreatic cancer (Schuler et al., 2010) .
Disruption of cell-cycle checkpoints
Various cell-cycle checkpoints are known to be dysregulated in transformed cells (Kastan and Bartek, 2004) . It has been postulated that in normal cells, HDACis trigger a G 2 -phase checkpoint, leading to cellcycle arrest, whereas in their transformed counterparts, HDACis cause cells to enter an aberrant mitosis, culminating in cell death (Warrener et al., 2003) . , one of the most commonly induced genes by HDACis, and potently induce its expression in diverse transformed cell types independently of p53, leading to cell-cycle arrest (Ocker and Schneider-Stock, 2007; Zupkovitz et al., 2010) . Decreased levels of cyclins by HDACis may contribute to cell-cycle arrest by causing the dephosphorylation of Rb and inhibition of E2F. Interestingly, disruption of p21 CIP1/WAF1 induction by either genetic or pharmacologic means markedly increases HDACi lethality (Almenara et al., 2002) . A recent study showed that induction of p21 by HDACi was linked to simultaneous acetylation and phosphorylation of histone H3 (Simboeck et al., 2010) . Association of the phosphobinding protein 14-3-3z to this H3S10phK14ac dual modification mark at the activated p21 promoter protects it from being processed by PP2A. This work uncovered a new type of cross-talk between reversible phosphorylation and acetylation signals that controls the activation of p21 by HDACis (Simboeck et al., 2010) .
Disruption of chaperone function
Specific inhibitors of HDAC6, whose major substrate is a-tubulin, also increase the acetylation of heat-shock proteins such as Hsp90 (Neckers and Ivy, 2003) . Hsp90 is an abundant cellular chaperone whose overexpression in tumor cells correlates with resistance to chemotherapy (Whitesell and Lindquist, 2005) . Hsp90 is in a multiprotein complex that includes Hsp70, binds to many different client proteins, including key oncogenic and antiapoptotic proteins, and prevents their ubiquitinylation and proteasomal degradation. Thus, inhibiting HDAC6 leads to the proteasomal degradation of its 'client proteins,' including HER2/neu, ERBB1, ERBB2, Akt, c-Raf, Bcr/Abl and FLT3, among others, in transformed cells (Bali et al., 2004; Fiskus et al., 2006) , leading to blockade of many cancer-causing pathways and the antagonism of the hallmark traits of malignancy (Workman et al., 2007) . Specific inhibitors of HDAC6 such as tubacin have been shown to interact synergistically with proteasome inhibitors such as bortezomib to kill multiple myeloma and Burkitt's lymphoma cells (Kawada et al., 2009) . The pan-HDACi panobinostat also increased the acetylation of the Hsp90 and reduced the chaperone association between CXCR4 and Hsp90, directing CXCR4 to degradation by the proteasome. In agreement, co-treatment with panobinostat and a CXCR4 antagonist synergistically induced the apoptosis of acute myeloid leukemia cells, supporting the rationale for testing their efficacy against acute myeloid leukemia (Mandawat et al., 2010) .
Activation of stress-related signaling cascades and ceramide generation HDACis, acting through multiple mechanisms, including induction of oxidative injury, can signal through the stress-related JNK pathway to trigger apoptosis in transformed cells . HDACis can also inhibit cytoprotective signaling pathways, including those related to MAPK/ERK kinase-1 (MEK1)/2/ ERK1/2 and AKT , thereby shifting the balance away from cell survival and toward cell death. The lethality of HDACis, administered either alone or in combination with nucleoside analogs such as fludarabine, or with inhibitors of AKT, have been attributed to the acid sphingomyelinase-dependent generation of the proapoptotic sphingolipid metabolite ceramide . Similarly, low doses of the multi-kinase inhibitor sorafenib and vorinostat interact in a synergistic manner to kill carcinoma cells by causing an increase in ceramide formation. Ceramide in turn permits CD95 plasma membrane localization and activation, leading to the induction of at least three immediate downstream survival-regulatory signals: activation of pro-caspase-8 (death), activation of PERKeIF2a-ER stress (death) and activation of PERK-ATG5-autophagy (survival) (Park et al., 2008) . In this regard, recent findings showed that elevation of cytosolic calcium in gastrointestinal tumor cells by sorafenib and vorinostat is a primary event that increases dihydroceramide levels, which is essential for ROS generation and activation of PP2A, which promotes CD95 activation (Park et al., 2010) . Although cell killing by this targeted therapy correlated with ceramide synthase-6 (Cers6) expression (Walker et al., 2009; Park et al., 2010) , interestingly, generation of C18-ceramide through the expression of Cers1, and not C16-ceramide by Cers5 or Cers6 expression, resulted in the repression of the human telomerase reverse transcriptase promoter through deacetylation of Sp3 by HDAC1 in A549 human lung adenocarcinoma cells (WootenBlanks et al., 2007) . Mechanistically, increased generation of C18-ceramide by CerS1 expression mediated the association and the recruitment of the deacetylated Sp3/ HDAC1 complex to the telomerase reverse transcriptase promoter, resulting in local histone H3 deacetylation and repression of the promoter (Wooten-Blanks et al., 2007) .
Induction of oxidative injury
While it has long been known that HDACis trigger the generation of ROS in transformed cells (Ruefli et al., 2001) , the mechanism by which this phenomenon occurs remains to be elucidated. It has been proposed that the selective toxicity that HDACis exert toward transformed cells stems from differential effects on antioxidant proteins, including manganese superoxide dismutase 2 (Mn-SOD2), and particularly thioredoxin (Ungerstedt et al., 2005) . Notably, administration of antioxidants (for example, TBAP, a cell-permeable superoxide dismutase mimic) has been shown to protect cells from both HDACi-induced DNA damage and lethality . Addition of phenylethyl isothiocyanate, a natural compound capable of depleting cellular glutathione, significantly enhanced the cytotoxicity of vorinostat in leukemia by inhibiting the cytoprotective antioxidant response. These results suggest that a combination with a redox-modulating compound increases sensitivity to HDACis to overcome resistance (Hu et al., 2010) . Despite strong evidence that ROS are responsible for DNA damage in transformed cells exposed to HDACis (Rosato et al., 2008 ), the precise mechanism by which HDACis induce ROS, as well as the source of the ROS, remain to be defined.
Perturbations in NF-kB
There is accumulating evidence that the NF-kB transcription factor family has a key role in integrating oxidative stress, DNA-damage and cell death responses to HDACis. HDACis, like tumor necrosis factor-a, activate RelA, but in contrast to the tumor necrosis factor-a responses, which are terminated by the re-synthesis of the NF-kB-inhibitory protein IkBa, HDACi-mediated NF-kB activation tends to be sustained (Chen and Greene, 2004) . This most likely reflects the acetylation and phosphorylation of RelA, which promote its binding to DNA while inhibiting its nuclear export (Chen et al., 2001 (Chen et al., , 2005 . Significantly, activation of NF-kB initiates events that protect cells from HDACi lethality, including induction of Mn-SOD, which scavenges ROS, and upregulation of antiapoptotic proteins such as Bcl-xL and XIAP, which attenuate apoptosis . A corollary of this model is that agents that block the activation of NF-kB by HDACis would be predicted to enhance lethality. This has been shown to be the case in studies involving proteasome inhibitors, which block IkBa degradation (Dai et al., 2008a) , or IKK inhibitors, which block IkBa phosphorylation and ubiquitination (Dai et al., , 2010 .
Until recently, the mechanism by which HDACis triggered NF-kB activation remained obscure. However, recent evidence suggests that this most likely occurs through the atypical, 'inside-out' ATM/NEMO DNA damage-related NF-kB activation pathway (Figure 3) . In this pathway, DNA damage induces the SUMOylation of NEMO, the IKK-regulatory subunit, which traps it in the nucleus. Concurrently, the kinase ataxia telangiectasia mutated (ATM) is activated, leading to phosphorylation of the complex, removal of SUMO residues and export of the NEMO complex to the cytoplasm, where it activates IKK, in a manner dependent on another IKK regulator, a protein rich in glutamate, leucine, lysine and serine (ELKS), resulting in IkBa phosphorylation and proteasomal degradation (Wu et al., 2006) (Figure 3) . Two reports recently suggested Histone deacetylase inhibitors in cancer therapy S Spiegel et al that after activation, ATM is exported from the nucleus and stimulates the ubiquitin ligase activity of TRAF6 or XIAP, causing the poly-ubiquitination of TRAF6 and the IKK adaptor ELKS (Hinz et al., 2010; Wu et al., 2010) . The ubiquitination promotes the recruitment of the kinase TAK1 and the activation of the cytosolic IKK complex, which then phosphorylates IkBa. This in turn leads to the release and the nuclear translocation of p65/RelA, and the transcriptional activation of multiple NF-kB-dependent genes, including the ROS scavenger Mn-SOD2, which eliminates ROS and limits further DNA damage and cell death. Recently, it has been shown that HDACis, by inducing ROS and DNA damage in leukemia cells, activate ATM, which leads to the nuclear export of NEMO followed by NF-kB induction, upregulation of Mn-SOD2 and elimination of ROS (Rosato et al., 2010) (Figure 3) . Notably, knockdown of ATM or transfection of cells with vectors expressing a mutant form of NEMO lacking SUMOylation sites substantially reduced HDACi-mediated NF-kB activation, associated with increased ROS generation; DNAdamage induction, reflected by increased expression of phosphorylated histone H2AX (gH2AX), a marker of DNA double-strand breaks; and cell death. Therefore, the initial induction of ROS by HDACis and the resulting DNA damage are critical for NF-kB activation, which, through induction of Mn-SOD2 and ROS elimination, limit further genotoxic stress and lethality. A corollary of this notion is that interruption of HDACi-mediated NF-kB activation and potentiation of lethality may occur by two mechanisms: interference with IKK activation and/or RelA acetylation, and disruption of the ATM/NEMO DNA damage-related pathway (Rosato et al., 2010) . The implication of these findings is that the ATM/NEMO/SUMOylation-related NF-kB activation pathway may have a key role in integrating oxidative injury, DNA-damage and cell death responses in transformed cells exposed to HDACis, and suggest that blocking NF-kB activation through the atypical ATM/NEMO nuclear pathway can enhance HDACi lethality.
DNA-damage responses
The preceding findings, as well as the results of several other recent studies, suggest that among their many actions, modulation of DNA-damage responses has an important role in the biological effects of HDACis in transformed cells. For example, the rapid induction of DNA damage, manifested by gH2AX formation and ATM phosphorylation, has been invoked to explain the preferential induction of cell death in leukemia versus in normal cells (Gaymes et al., 2006) . As noted above, HDACi-mediated DNA damage most likely stems from the induction of oxidative injury Rosato et al., 2008) . In addition to triggering DNA damage through ROS generation, evidence is now accumulating that HDACis may also act by disrupting DNA-repair processes at multiple levels. For example, as noted previously, HDACis may prevent deacetylation and disrupt the function of DNA-repair proteins such as Ku70 by preventing it from suppressing Bax-mediated apoptosis Subramanian et al., 2005) . Second, HDACis may act through a transcriptional mechanism to downregulate various DNA-repair proteins, for example, RAD50, RAD51 and MRE11 (Rosato et al., 2008; Lee et al., 2010a) . Furthermore, these events may occur preferentially in transformed cells (Lee et al., 2010a) . Indeed, in transformed cells, the levels of phosphorylated gH2AX increased with continued culture with vorinostat, whereas this marker decreased with time in normal cells (Lee et al., 2010a) . Thus, HDACis like vorinostat can induce DNA damage that normal but not cancer cells can repair, and explain, in part, the selectivity of vorinostat in the induction of cancer cell death at concentrations that do not kill normal cells (Lee et al., 2010a) . In addition, there is evidence that HDACs participate in the DNA-repair process. For example, deletion of HDAC3 has been shown to increase DNA damage and to disrupt the Sphase checkpoint in mouse embryonic fibroblast cells (Bhaskara et al., 2008) . Finally, recent studies suggest that HDACs may have a role in both homologous and non-homologous end-joining DNA repair, events that may be disrupted by HDACis (Kachhap et al., 2010; Miller et al., 2010) . Thus, HDACis may promote lethal DNA damage through multiple interactive mechanisms, including induction of ROS, downregulation of antioxidant proteins, disabling and downregulation of DNA-repair proteins, and interference with proteins involved in homologous recombination and non-homologous end-joining repair.
Endogenous HDACis
Sodium butyrate, a short-chain fatty acid formed by fermentation of dietary fibers by the microbial flora of the colon, was the first natural product discovered to be an inhibitor of HDAC activity (Candido et al., 1978) . It induces cell-cycle arrest, differentiation and apoptosis in various types of cancer cells, and inhibition of HDAC seems to have a central role in these responses. Butyrate was thus suggested to act as a chemopreventive metabolite that can prevent the occurrence of colorectal cancer. It was later discovered that the ubiquitous metabolite pyruvate is also an HDACi (Thangaraju et al., 2006) . It has long been known that tumor cells depend on glycolysis, but they convert pyruvate into lactate instead of oxidizing it in the mitochondria (Warburg, 1956 ), a phenomenon termed the 'Warburg effect'. Interestingly, pyruvate, but not lactate, inhibits HDACs and induces tumor cell-specific apoptosis (Thangaraju et al., 2006) . The tumor suppressor SLC5A8 (SMCT1), an Na þ -coupled co-transporter for short-chain fatty acids (acetate, propionate and butyrate), is downregulated by cancer cells as a complementary mechanism to evade pyruvate lethality (Thangaraju et al., 2006) . Surprisingly, however, despite the development of numerous short-chain fatty acid analogs as drugs that inhibit HDACs that are now in clinical trials, little progress has been made in further understanding the physiological regulators of HDAC activity. Recently, the potent sphingolipid metabolite sphingosine-1-phosphate (S1P) was shown to be produced in the nucleus and act as an endogenous HDACi. Although sphingomyelin, the membrane sphingolipid precursor of S1P, has long been known to be a component of the nuclear matrix (Cocco et al., 1980) , the possibility that sphingolipids are also metabolized within the nucleus has only recently emerged from the observations that enzymes that metabolize sphingomyelin are present there. These include sphingomyelinase, which hydrolyzes sphingomyelin to ceramide, and ceramidase, which cleaves ceramide to sphingosine (Albi et al., 2008) , which is then phosphorylated by sphingosine kinase-2 (SphK2) to S1P (Igarashi et al., 2003; Sankala et al., 2007) . S1P is a pleiotropic signaling lipid that regulates many cellular processes important for cancer progression, including cell growth and survival, invasion, angiogenesis, lymphocyte trafficking and inflammation, among others (Spiegel and Milstien, 2003) . S1P is produced inside cells by two closely related sphingosine kinases, SphK1 and SphK2 , and is exported out, where it regulates many of these functions by binding to and signaling through a family of five G-protein-coupled receptors, now designated S1P 1À5 , in a process known as 'inside-out' signaling (Figure 4) . SphK1, which is mainly cytosolic and translocated to the plasma membrane after stimulation by growth factors and cytokines, but not SphK2, is involved in S1P export from cancer cells, mediated by the ATP-binding cassette transporters ABCC1 and ABCG2 (Takabe et al., 2010) . There is no doubt that there are links between SphK1 and cancer. Overexpression of SphK1 enhances cell growth, survival and resistance to chemotherapeutics, whereas overexpression of SphK2 reduces proliferation. SphK1 regulates the motility and invasiveness of tumor cells, and enhances tumorigenesis and angiogenesis. Moreover, the expression and abundance of SphK1 is increased in many types of human cancers, and there are correlations between its expression and poor prognosis (Shida et al., 2008) . Yet much less has been learned about the functions of SphK2, which is present in the nucleus of many cancer cells (Figure 4) . Surprisingly, it was recently reported that the nucleus contains a large fraction of cellular sphingosine and dihydrosphingosine, which lacks the trans double bond at the position 4, and that SphK2 expression significantly increased the nuclear levels of S1P and dihydro-S1P. Expression of SphK2, but not catalytically inactive Figure 4 Inside-out signaling by S1P. The binding of growth factors (for example, EGF) to their tyrosine kinase receptors activates ERK1, which then phosphorylates cytosolic SphK1, leading to its translocation to the plasma membrane where its substrate sphingosine resides. In some cells, SphK2 is at the plasma membrane and can also be activated by ERK1 phosphorylation. Once produced, S1P can be exported out of the cells by ABC transporters to activate cell-surface S1P receptors in an autocrine or paracrine manner, known as 'inside-out signaling by S1P'. This leads to the activation of multiple signals downstream from G-proteins important for tumorigenesis, including growth, survival, motility, invasion and regulation of gene expression. In many types of cancer cells, SphK2 is predominantly in the nucleus, where it produces S1P, which inhibits class-I HDACs.
Histone deacetylase inhibitors in cancer therapy S Spiegel et al SphK2 or SphK1, increased the acetylation of the lysine-9 of histone H3, lysine-5 of histone H4 and lysine-12 of histone H2B without affecting the acetylation of histone H2A. Conversely, depletion of SphK2, which specifically reduced the levels of S1P and dihyrdro-S1P in the nucleus, decreased the acetylation of the same histone lysine residues. In agreement, addition of S1P or dihydro-S1P to isolated nuclei further enhanced the acetylation of these histone lysines (Hait et al., 2009) . Importantly, both S1P and dihydro-S1P potently inhibited the in vitro enzymatic activities of recombinant and purified HDAC1 and HDAC2, which explains their effects on the enhancement of histone acetylations (Hait et al., 2009) . Several methods were used to show that HDAC1 and HDAC2 are indeed bona fide intracellular targets of S1P. First, endogenous HDAC1 and HDAC2 were pulled down specifically by S1P immobilized on affinity matrices. By contrast, neither class-IIa (HDAC4, HDAC5, HDAC7) nor class-IIb HDACs (HDAC6), or sirtuins, bound to the S1P matrices. Second, sphingolipid mass spectrometry showed that of all of the sphingolipids present in the nucleus, only endogenous S1P was bound to nuclear HDAC1. Finally, S1P and dihydro-S1P, but not any other related lipids, specifically displaced the bound S1P from HDAC1 and HDAC2. Similarly, both suberoylanilide hydroxamic acid (SAHA) and trichostatin-A, potent inhibitors of HDACs, also competed with S1P for binding to HDAC1 and HDAC2, suggesting that they shared similar or overlapping binding sites. Indeed, molecular modeling of S1P into the active site of the HDAC1 homolog from the hyper-thermophilic bacterium Aquifex aeolicus histone deacetylase-like protein (HDLP) indicated that it docked as well as SAHA, with estimated K i values by AutoDock of 9.47eÀ06 and 6.32eÀ06 for S1P and SAHA, respectively (Hait et al., 2009) . This conserved HDAC active site consists of a tubular pocket with a zinc-binding site at the base, two Asp-His charge-relay systems and a tyrosine residue that stabilizes the tetrahedral oxyanion necessary for catalysis (Finnin et al., 1999; Hodawadekar and Marmorstein, 2007) . Interestingly, molecular modeling predicted that Tyr297 in HDLP, which is important for catalysis, and Arg27 (Arg34 in HDAC1), a highly conserved residue in close proximity to Tyr297 (Finnin et al., 1999; Hodawadekar and Marmorstein, 2007) , form hydrogen bonds with the phosphate group of S1P (Hait et al., 2009) , providing a potential explanation of its inhibition of HDAC activity by S1P.
What then are the consequences of inhibition of HDAC1 and HDAC2 by S1P? As induction of p21 expression is one of the common responses to the inhibition of HDAC1 and HDAC2, not surprisingly, SphK2 upregulates p21 expression in a p53-independent manner (Sankala et al., 2007) (Figure 5 ). SphK2 associates with HDAC1/2 in repressor complexes and is selectively enriched at the proximal p21 promoter, where it enhances local histone H3K9 acetylation, leading to chromatin reorganization and enhanced gene transcription (Hait et al., 2009) . In agreement, downregulation of SphK2 decreased the basal and doxorubicin-induced Figure 5 The role of S1P formed in the nucleus by SphK2 in the regulation of histone acetylation and p21 expression. Activation ofSphK2 nuclear activation leads to the formation of S1P, which inhibits HDAC1 and HDAC2, leading to increased histone acetylation p21 gene expression. In response to DNA damage (doxorubicin), p53 is upregulated, which leads to the induction of BAX, NOXA and PUMA (cell death mediators), and also induces p21, which suppresses apoptosis and induces cell-cycle arrest. Downregulation of SphK2 prevents the induction of p21 and removes the p21-mediated protection against apoptosis, facilitating cell death.
expression of p21 without affecting the increased expression of p53. Downregulation of SphK2 also decreased the G(2)-M arrest and markedly enhanced the apoptosis induced by doxorubicin. Likewise, in human wild-type, p53-expressing HCT116 colon carcinoma cells, as well as in their p53-null counterparts, SphK2 depletion also markedly reduced the p21 induction by doxorubicin and sensitized the HCT116 cells to apoptosis induced by doxorubicin. These results further support the notion that endogenous SphK2 is important for the p53-independent induction of p21 expression ( Figure 5 ). Upregulation of p53 by doxorubicin is not only important for the induction of p21 but also of several proapoptotic proteins, including PUMA and NOXA. However, these lead to apoptosis only in the absence of p21, which can suppress apoptosis (Seoane et al., 2002) . Downregulation of SphK2 expression represses p21 and switches the response from cell-cycle arrest to apoptosis, suggesting that SphK2 may influence the balance between cytostasis and apoptosis of cancer cells ( Figure 5 ).
Nuclear SphK2 and S1P also similarly regulated the expression of c-fos, another well-known HDAC1-regulated gene (Hait et al., 2009) . Interestingly, phorbol 12-myristate 13-acetate, which enhances the extracellular signal-regulated kinase-1 (ERK1)-dependent phosphorylation of SphK2 and its catalytic activity , transiently increased S1P in the nucleus and also rapidly enhanced the colocalization of SphK2 with HDAC1 (Hait et al., 2009) . At later time points, phorbol 12-myristate 13-acetate induced the protein kinase-Dmediated phosphorylation of serine residues within the nuclear export signal of SphK2 (Ding et al., 2007) , resulting in its export from the nucleus to ensure transient inhibition of HDACs. Although there is still much more to be learned about the physiological stimuli that regulate SphK2 and S1P synthesis in the nucleus, Hait et al. (2009) provided the first demonstration that S1P formed by nuclear SphK2 in response to environmental signals influences the turnover of histone acetylation and the transcription of target genes, linking S1P and sphingolipid metabolism in the nucleus to the remodeling of chromatin and the epigenetic regulation of gene expression.
Conclusions, questions and future perspectives
Despite the widespread interest in HDACs, the environmental cues, the signal transduction pathways regulating their activity and endogenous regulators remain largely unknown. The finding that S1P and SphK2 are part of a co-repressor complex that influences histone acetylation and gene expression (Hait et al., 2009) suggests an intriguing paradigm for sphingolipid signaling in the nucleus and for HDAC regulation. Further studies may provide new clues to unresolved questions regarding specificity: How do distinct signaling pathways influence HDAC-dependent gene repression and determine the choice of acetylated targets? Deciphering the role of S1P in the regulation of histone acetylation is important as HDACis represent a promising new therapeutic approach for cancer treatment. In this context, it will be particularly important to gain an improved understanding of how HDACs are regulated as well as the mechanisms by which HDACis exert their lethal effects toward tumor cells. To this end, a substantial number of questions remain to be answered. For example, an explanation for the selective ability of HDACis to kill transformed but not normal cells, at least in the preclinical setting, remains to be identified. Although initial clues suggest impaired antioxidant and DNAdamage defenses in the former, this needs to be validated. In addition, the relative advantages of isoformspecific versus non-specific HDACis remain a subject of considerable debate. While it is possible that isoformspecific inhibitors may be relatively free of undesirable toxicities, it is also conceivable that agents that inhibit both nuclear (for example, class-I) and cytoplasmic HDACs (for example, class-IIb) may offer therapeutic advantages by simultaneously targeting multiple processes, that is, gene transcription as well as protein disposition. For the immediate future, important questions involving HDACis to be addressed include deciphering their precise relationship to DNA-damage responses, their complex bidirectional interactions with transcription factors (for example, NF-kB) and corepressors, and the nature of their interactions with other agents that modify the epigenome, for example, DNMTIs, histone methyltransferases and histone demethylases. Complicating these tasks is the likelihood that HDACis undoubtedly act simultaneously through multiple interrelated mechanisms to exert their biological effects, for example, through alterations in chromatin structure and gene expression, induction of oxidative injury and DNA damage, modification of the expression and function of chaperone and repair proteins, and interactions with transcription factors and co-repressor proteins. Despite the obvious challenges, answers to these questions will greatly facilitate the search for safer and more effective drugs capable of interfering with HDAC functions in a highly specific manner.
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